Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer By Ogkologos - August 17, 2026 121 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PSMAddition study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas... September 29, 2026 Coronavírus e COVID-19: o que as pessoas com câncer precisam saber June 22, 2020 Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... June 15, 2023 One Year of Adjuvant T-DM1 Leads to Outstanding Long-Term Outcomes Among... July 18, 2024 Load more HOT NEWS Young Women At Increased Risk Of Aggressive Breast Cancer First-Line Nivolumab Plus Chemotherapy and Nivolumab Plus Ipilimumab Continue to Demonstrate... Using Immunotherapy to Treat Advanced Melanoma and Advanced Non-Small Cell Lung... Coping With Life After a Bone Marrow Transplant: A Survivor’s Story
